Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 24, 2020Journal of the American Society of NephrologyOpen Access

Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial

View Full Paper
Ask AI
Bookmark
Share

Authors

MJMeg JardineThe University of SydneyZZZien ZhouShanghai Jiao Tong University
Kenneth W. Mahaffey
Kenneth W. MahaffeyCross-Cutting Cardiology

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Jardine et al. (2020) studied this question.

synapsesocial.com/papers/6a86cd1246ba7ceb229eabebhttps://doi.org/10.1681/asn.2019111168
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy2019 · 6,236 citations
  2. 2Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus2013 · 1,334 citations
  3. 3Salt-Responsive Metabolite, β-Hydroxybutyrate, Attenuates Hypertension2018 · 176 citations
  4. 4Elevated plasma atrial natriuretic peptide levels in diabetic rats. Potential mediator of hyperfiltration.1987 · 194 citations
  5. 5Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT22018 · 351 citations